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doi:10.1016/j.hkjn.2012.01.003Summary World Kidney Day on March 8, 2012, provides a chance to reflect on the success of
kidney transplantationasa therapy forendstagekidneydisease that surpassesdialysis treatments
both for thequalityandquantityof life that itprovides and for its cost effectiveness.Anything that
is both cheaper and better, but is not actually the dominant therapy, must have other drawbacks
that prevent replacement of all dialysis treatment by transplantation. The barriers to universal
transplantation as the therapy for end stage kidney disease include the economic limitations,
which, in some countries place transplantation, appropriately, at a lower priority than public
health fundamentals such as clean water, sanitation and vaccination. Even in high income coun-
tries the technical challenges of surgery and the consequences of immunosuppression restrict the
number of suitable recipients, but themajor finite restrictions on kidney transplantation rates are
the shortage of donated organs and the limitedmedical, surgical, andnursingworkforceswith the
required expertise. These problems have solutions that involve the full range of societal, profes-
sional, governmental, and political environments. World Kidney Day is a call to deliver transplan-
tation therapy to the 1 million people a year who have a right to benefit.
在2012年3月8日舉行的世界腎臟日，讓我們再度檢視腎臟移植療法在治療末期腎病上所取得的
成果，無論在患者死亡率、生活品質、或成本效益方面，腎臟移植療法均超越了透析療法。然
而，基於多方面的原因，腎臟移植療法至今仍然未能全面取代透析療法的地位，例如某些國家基
於經濟上的限制，使得腎臟移植的優先順序位列於潔淨水源、環境衛生、及疫苗接種等公衛基本
環節之後。即使在較富裕的國家中，手術的技術需求及免疫抑制的後遺症，亦限制了適合接受移
植的個案數目；但是腎臟移植普及化的主要限制性因素，仍然是捐贈器官來源的短缺及具經驗醫
護人手的不足。為解決這些問題，必須依靠社會、專業團體、政府、及政治力量的共同努力。世
界腎臟日提醒了我們，要致力為每年一百萬的合資格患者，提供他們所需的腎臟移植療法。Kidney Day, International Society of Nephrology, Rue des Fabriques 1, 1000 Brussels, Belgium.
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patients.6 African American kidney transplant recipientsKidney transplantation is acknowledged as a major advance
of modern medicine that provides high-quality life years to
patients with irreversible kidney failure [end-stage renal
disease (ESRD)] worldwide. What was an experimental,
risky, and very limited treatment option 50 years ago is now
routine clinical practice in more than 80 countries. What
was once limited to a few individuals in a small number of
leading academic centers in high income economies is now
transforming lives as a routine procedure in most high- and
middle-income countriesdbut can do much more. The
largest numbers of transplants are performed in the United
States, China, Brazil, and India, while the greatest pop-
ulation access to transplantation is in Austria, the United
States, Croatia, Norway, Portugal, and Spain. There are still
many limitations in access to transplantation across the
globe. World Kidney Day on March 8, 2012, will bring
focus to the tremendous life-changing potential of kidney
transplantation as a challenge to politicians, corporations,
charitable organizations, and healthcare professionals. This
commentary raises awareness of the progressive success
of organ transplantation and highlights concerns about
restricted community access and human organ trafficking
and commercialism, while also exploring the real potential
for transforming kidney transplantation into the routine
treatment option for ESRD across the world.
Outcomes of kidney transplantation
The first successful organ transplantation is widely acknowl-
edged to be a kidney transplant between identical twins
performed in Boston on December 23, 1954, which heralded
the start of a new era for patients with ESRD.1
In the development years between 1965 and 1980,
patient survival progressively improved toward 90% and
graft survival rose from less than 50% at 1 year to at least
60% after a first deceased donor kidney transplant, based
on immunosuppression with azathioprine and prednisolone.
The introduction of ciclosporin in the mid 1980s was
a major advance, leading to 1-year survival rates of more
than 90% and graft survival of 80%.2 In the last 20 years,
better understanding of the benefits of combined immu-
nosuppressant drugs coupled with improved organ matching
and preservation, as well as chemoprophylaxis of opportu-
nistic infections, have all contributed to a progressive
improvement in clinical outcomes. Desensitized recipients
of first deceased donor kidney transplants and living donor
recipients can now expect 1-year patient and transplant
survival to be at least 95% and 90%, respectively.1 New
developments have led several groups to report excellent
results even from carefully selected ABO blood-groupe
incompatible transplants in recipients with low titer
ABO-antibodies.3 Even for those with high titers of donor
specific human leukocyte antigen (HLA)-antibodies, who
were previously untransplantable, better desensitization
protocols4 and paired kidney exchange programs5 now
afford real opportunities for successful transplantation.
Ethnic minorities and disadvantaged populations continue
to experience worse outcomes; Aboriginal Canadians, for
example, have lower 10-year patient (50% vs. 75%) andgraft (26% vs. 47%) survival compared with Caucasian
have shorter graft survival compared with Asian, Hispanic,
and Caucasian populations in the United States.7 In New
Zealand, Maori, and the Pacific Islands, recipients of
deceased donor transplants have a 50% 8-year graft survival
compared with 14 years for nonindigenous recipients, in
part due to differences inmortality.8 By contrast, despite
a resource poor environment, Rizvi and others9 report 1-
and 5-year survival rates of 92% and 85%, respectively,
among 2249 living related kidney transplants in Pakistan,
whilst in Mexico, 90% and 80% 1-year survival for living and
deceased donor kidney transplants were reported among
1356 transplants performed at a single center.10 But, while
it is possible to achieve such excellent long-term results,
most patients and their families in resource-poor (less
wealthy) environments cannot afford the high cost of
immunosuppressants and antiviral medications needed to
reduce the risk of graft loss and mortality.11Place of kidney transplantation in treatment
for ESRD
Kidney transplantation improves long-term survival compared
with maintenance dialysis. In 46,164 patients on the trans-
plant waiting list in the United States between 1991e1997,
mortality was 68% lower for transplant recipients than for
those remaining on the transplant waiting list after more than
3 years of follow-up.12 The transplanted 20e39-year-old
patients of both sexes were predicted to live 17 years longer
than those remaining on the transplant waiting list, an effect
that was even more marked in patients with diabetes.
The number of people known to have ESRD worldwide is
growing rapidly as a result of improved diagnostic capabil-
ities and also the global epidemic of type 2 diabetes and
other causes of chronic kidney disease (CKD). Dialysis costs
are expensive even for developed countries, but they are
prohibitive for many emerging economies. The majority of
patients commencing dialysis for ESRD in low-income
countries die or stop treatment within the first 3 months
of initiating dialysis due to cost restraints.13 The cost of
maintenance hemodialysis varies considerably by country
and healthcare system. In Pakistan, maintenance hemodi-
alysis is reported to be $1680 per year, which is beyond
the reach of most of the population without humanitarian
financial aid.14 Despite exemplars, both provision of
hemodialysis facilities and uptake of peritoneal dialysis
remain very limited in middle- and low-income countries.
Whilst the costs of transplantation exceed those of main-
tenance dialysis in the first year post-transplantation (e.g.,
in Pakistan, this is $5245 vs. $1680 in the first year), the
costs are reduced compared with dialysis in subsequent
years, especially with the advent of inexpensive generic
immunosuppression.15 Transplantation thus expands access
and reduces overall costs for successful treatment of ESRD.
Preemptive transplantation is an attractive option for
both patients and payers with both reduced costs and
improved graft survival.16 Preemptive transplantation is
associated with a 25% reduction in transplant failure and
16% reduction in mortality compared with recipients
receiving a transplant after starting dialysis.17
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thus the treatment of choice for patients with ESRD
because of lower costs and better outcomes.Global disparities in access to kidney
transplantation
Substantial disparities in access to transplantation across
the world are demonstrated in Fig. 1 [derived from the
World Health Organization/Organization Mondiale de la
Sante´ (WHO/OMS) Global Observatory on Donation and
Transplantation],18 which demonstrates the relationship
between transplant rate and the Human Development
Index (HDI). There is a reduced transplant rate in low and
middle HDI countries, and a large spread of transplant rates
even amongst the richer nations. Transplant rates of more
than 30 per million population (pmp) in 2010 were
restricted to Western Europe, the United States, and
Australia, with a slightly broader spread of countries
achieving between 20 and 30 pmp. The rates in Asia are
generally low, although the number of transplants is espe-
cially high in China.
There are also within-country disparities in transplant
rates among minorities and other disadvantaged pop-
ulations. In Canada, all minority groups have significantly
lower transplant rates; compared with Caucasians, rates in
Aboriginal and African Canadians, Indo Asians, and East
Asians were 46%, 34%, and 31%, lower respectively.19 In the
United States, transplantation rates are significantly lower
among African Americans, women, and the poor, compared
with Caucasians, men, and the more affluent populations.20
The situation is similar in Australia where Aboriginal
Australians fare worse than nonindigenous Australians (12%
vs. 45%) and in New Zealand where Maori and PacificFigure 1 Number of deceased and living donor kidney transplan
2010, correlated with the Human Development Index. Grouped by
Mediterranean; EURZ Europe; SEARZ South Eastern Asia; WPRZIslanders are disadvantaged (14% vs. 53%).21 In Mexico, the
transplant rate among uninsured patients is 7 pmp compared
with 72 pmp among those with health insurance.22
Multiple immunologic and nonimmunologic factors
contribute to social, cultural, and economic disparities in
transplant outcomes, including biologic, immune, genetic,
metabolic, and pharmacologic factors as well as associated
comorbidities, time on dialysis, donor and organ charac-
teristics, patient socioeconomic status, medication adher-
ence, access to care, and public health policies.7 Developing
countries often have especially poor transplant rates not
only because of these multiple interacting factors, but
also because of inferior infrastructure and an insufficient
trained workforce. Deceased donation rates may also be
impacted by lack of a legal framework governing brain
death and by religious, cultural, and social constraints.
When these factors are all compounded by patient anxieties
about the success of transplantation, physician bias,
commercial incentives favoring dialysis, and geographic
remoteness, poor access to transplantation is almost inevi-
table for most of the world’s population.
Improving access to transplantation
Both living donation and deceased donor donation are now
recognized by the WHO as critical to the capacity of nations
to develop self-sufficiency for organ transplantation.23 No
country in the world, however, generates sufficient organs
from these sources to meet the needs of their citizens.
Austria, the United States, Croatia, Norway, Portugal, and
Spain stand out as countries with high rates of deceased
organ donors, and most developed countries are trying to
emulate their success. A return to ‘donation after cardiac
death’ instead of the now standard ‘donation after brain
death,’ has enhanced the deceased organ donationts in the World Health Organization (WHO) member states in
WHO regions. AFRZ Africa; AMRZ Americas; EMRZ Eastern
Western Pacific.
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donors pmp in the United States and 1.1 pmp in Australia
now emanating from this source. Protocols for rapid cooling
and urgent retrieval of kidneys after cardiac death, and, in
some circumstances other organs, have developed over the
past 5 years to reduce the duration and consequences of
warm ischemia.24 Another strategy for increasing the rate
of transplantation has been to extend the acceptance
criteria for deceased organ donors. Such ‘extended
criteria’ donors require additional consideration and
specific consent by the recipient. There is risk in accepting
an ‘extended criteria’ kidney since the transplants are less
successful in the long term, but also a risk to waiting longer
on dialysis for a standard criteria donor.
A number of strategies have been designed and imple-
mented to reduce disparities among disadvantaged pop-
ulations. The Transplantation Society has established the
Global Alliance for Transplantation in an effort to reduce
worldwide disparities in transplantation. The program
includes collecting global information, expanding educa-
tion about transplantation, and developing guidelines for
organ donation and transplantation. The International
Society of Nephrology (ISN) Global Outreach program has
catalyzed the development of kidney transplant programs
across a large number of countries with targeted fellowship
training and the creation of long-term institutional links
between developed and developing transplant centers
through its Sister Center Program. This has led to the
establishment of successful kidney transplantation in
countries such as Armenia, Ghana, and Nigeria where none
existed before as well as expansion of existing programs in
Belarus, Lithuania, and Tunisia.
A model of collaboration for dialysis and transplantation
between government and the community in the resource
poor world has been successfully established in Pakistan
with government assistance for infrastructure, utilities,
equipment, and up to 50% of the operating budget, while
the community, including affluent individuals, corpora-
tions, and the public, donate the remainder.14 In 2001, in
Central America, a specialized unit of pediatric nephrology
and urology was opened in Nicaragua with funds provided
initially by the Associazione per il Bambino Nefropatico,
a kidney foundation based in Milan, Italy, supplemented
by a consortium of private and public organizations,
including the International Pediatric Nephrology Associa-
tion and the Nicaraguan Ministry of Health. Subsequently,
the Nicaraguan government and a local kidney foundation
recognized the success of the program and accepted
gradual transfer of the costs of treatment, including the
provision of immunosuppressive medications for renal
transplantation. A similar successful partnership between
government and the private sector has recently been
reported in India.25
There are tremendous opportunities to correct dispar-
ities in kidney disease and transplantation worldwide, but it
is important to recognize that funding of ESRD treatment
should be associated with funding for early detection and
prevention of the progressive kidney diseases that lead to
ESRD. Comprehensive programs should include community
screening and prevention of CKD, especially in high-risk
populations, as well as dialysis and transplantation for
ESRD.An integrated approach to the expansion of trans-
plantation requires training programs for nephrologists,
transplant surgeons, nursing staff, and donor coordinators;
nationally funded organ procurement organizations
providing transparent and equitable retrieval and alloca-
tion; and the establishment of national ESRD registries.Ethical challenges and the legal environment
The impact of the global organ donor shortage and the
dramatic disparities demonstrated by the WHO data are
experienced in many different ways, requiring varied
responses. But one common factor is the relative wealth
of the nation and the individual. The poor receive the
fewest transplants and the rich are most often transplanted
either in their own country or through finding an organ
through illegal purchase from the poor or an executed
prisoner. Trafficking in human organs and commercializa-
tion of the beneficial act of organ donation were unusual
and extremely hazardous in the 1980s, but they became
frequent (but still very hazardous) in the 1990s, and now
have become a gruesomely burgeoning trade at the turn of
the century. The WHO has estimated that up to 10% of all
organ transplants were of commercial origin by 2005.26
The first WHO Guiding Principles in this field were agreed
upon 1991 and made clear by the decision of national
governments to ban commercialization of organ donation
and transplantation.27 This principle was reaffirmed unan-
imously by the World Health Assembly in 2010 when the
updated WHO Guiding Principles for human organ and
tissue donation and transplantation were endorsed.28
Almost all countries with transplantation programs and
even some without active programs have carried that ban
on commercialism through to their own legislation, making
it illegal to buy or sell organs. Sadly, this has not prevented
continuation of the trade illegally in countries such as China
and Pakistan, nor has it prevented new entrants to this
lucrative trade from taking advantage of their own or other
nations’ impoverished and vulnerable populations to
provide kidneys and even livers for the desperate wealthy
in need of transplantation.
Iran alone claims to have resolved national self-
sufficiency for kidney transplantation through a scheme of
a part-government, part patient-funded sale of kidneys by
vendors. The resultant slow development of deceased
organ donation in Iran restricting liver, heart, and lung
transplant programs, as well as the disparity of socioeco-
nomic status between donors and recipients, both testify to
the universality of the problems that arise from organ
transplant commercialization. The restriction of trans-
plantation to Iranian nationals only under this program has,
however, largely ensured that this national experiment has
not flowed on to create commercial organ trafficking across
Iranian national borders.
The Transplantation Society and the ISN have taken
a joint stand against the despoiling of transplantation
therapy and victimization of the poor and vulnerable by
doctors and other providers operating in these illegal
programs. In 2008, more than 150 representatives from
across the world from different disciplines of healthcare,
national policy development, law, and ethics came
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principles and standards for organ transplantation. The
resultant Declaration of Istanbul29 has now been endorsed
by more than 110 professional and governmental organi-
zations and implemented by many of these organizations
with a goal to eliminate transplant tourism and enhance the
ethical practice of transplantation globally.30
Summary
There remain major challenges to providing optimal treat-
ment for ESRD worldwide and a need, particularly in
low-income economies, to mandate more focus on
community screening and implementation of simple
measures to minimize progression of CKD. The recent
designation of renal disease as an important non-
communicable disease at the United Nations High Level
Meeting on non-communicable diseases (NCDs) is one
step in this direction.31 But early detection and prevention
programs will never prevent ESRD in everyone with CKD,
and kidney transplantation is an essential, viable, cost-
effective, and life-saving therapy that should be equally
available to all people in need. It may be the only tenable
long-term treatment option for ESRD in low-income coun-
tries since it is both cheaper and provides a better outcome
for patients than other treatment for ESRD. However, the
success of transplantation has not been delivered evenly
across the world, and substantial disparities still exist in
access to transplantation. We remain troubled by the
commercialization of living donor transplantation and the
exploitation of vulnerable populations for profit.
There are solutions available. These include demon-
strably successful models of kidney transplant programs in
many developing countries; growing availability of less
expensive generic immunosuppressive agents; improved
clinical training opportunities; governmental and profes-
sional guidelines legislating prohibition of commercializa-
tion and defining professional standards of ethical practice;
and a framework for each nation to develop self-sufficiency
in organ transplantation through a focus on both living
donation and especially nationally managed deceased
organ donation programs. The ISN and the Transplantation
Society have pledged to work together in coordinated joint
global outreach programs to help establish and grow
appropriate kidney transplant programs in low- and middle-
income countries utilizing their considerable joint exper-
tise. World Kidney Day 2012 provides a focus to help spread
this message to governments, all health authorities, and
communities across the world.
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